TMCnet News
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and DevelopmentSOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine learning platform to improve the discovery and development of therapeutic antibodies. GigaGen’s machine learning models predict and generate sequences of antibodies that best bind to specific targets and can be used to later generate novel recombinant antibodies against those targets for potential therapeutic application. Carter Keller, chief executive officer at GigaGen, commented, “This research demonstrates how GigaGen’s machine learning methods can be leveraged to mine and learn patterns in antibody sequences, offering further insights into antibody engineering, optimization and discovery. While the article focuses on two main oncology targets, PD-1 and CTLA-4, the potential application of our technology is widespread to multiple disease targets, and we are excited to continue exploring its applicability in the future.” About Grifols A pioneer in the blood products industry, Grifols is one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. A a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it provides hospitals, pharmacies and health professionals with the tools, information and services that contribute to offering specialized and efficient medical care. Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that helps define the standards of continuous innovation, quality, safety and ethical leadership in the sector. In 2021, Grifols’ total economic impact in the main countries where it operates is estimated at 7,700 million euros and 141,500 jobs generated, including direct, indirect and induced jobs. The company's ordinary shares (Class A) are listed on the Spanish Continuous Market and form part of the Ibex-35 (MCE: GRF). Grifols non-voting shares (Class B) are listed on the Spanish Continuous Market (MCE: GRF.P) and on the North American NASDAQ through ADR (American Depositary Receipts) (NASDAQ: GRFS). GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. Its novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases. In addition, GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. For more information, please visit www.grifols.com or www.gigagen.com. Media Contacts: Grifols Press Office LEGAL DISCLAIMER
|